PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

Status Completed

Clinical Trial Summary

This study evaluates the responsiveness of the Platelet Function Analyzer (PFA-100) to the effect of energy drinks on platelet function. Participants' will have blood drawn prior to and 60 minutes after ingesting 250ml of a commercially available sugar-free energy drink.

Clinical Trial Description

Two previous studies have demonstrated increased platelet aggregation 60 minutes after drinking a commercially available sugar-free energy drink. These studies utilized traditional platelet function studies, such as light transmission aggregometry (LTA), where platelet function is examined while adding varying concentrations of a panel of agonist to platelets. These studies are technically difficult, time intensive studies requiring specialized laboratories. They are relatively non-physiologic and do not mimic platelet response to vessel wall damage. Other tests better represent the reactions to vessel wall damage, including the PFA-100, which measures platelet aggregation and adhesion under conditions of high shear.

Overall, PFA-100 is less expensive, requires less technical skill, and is less time consuming than LTA. It has been utilized in bleeding disorders and is demonstrating promise as a marker of thrombophilia. PFA-100 has demonstrated sensitivity to drug and dietary effects. It has also shown differences in closure time between sedentary and athletic individuals PFA-100 has not been used to investigate the effect of energy drinks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02997111
Study type	Interventional
Source	St. Louis University
Contact
Status	Completed
Phase	N/A
Start date	February 14, 2017
Completion date	June 20, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT05426564` - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Not yet recruiting	`NCT05830916` - Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02526628` - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed	`NCT02439190` - CV004-007 Thrombosis Chamber Study	Phase 1
Completed	`NCT02341638` - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT01855516` - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin	N/A
Unknown status	`NCT00983112` - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Completed	`NCT00346424` - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters	Phase 3
Terminated	`NCT00303420` - Alteplase for Blood Flow Restoration in Hemodialysis Catheters	Phase 4
Completed	`NCT00143715` - Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00007410` - Genetic Architecture of Plasma T-PA and PAI-1	N/A
Completed	`NCT00000538` - Dietary Effects on Lipoproteins and Thrombogenic Activity	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A